Livin Antibody
| Code | Size | Price |
|---|
| PSI-2505-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-2505-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
Livin Antibody: KIAP, LIVIN, MLIAP, RNF50, ML-IAP, KIAP, UNQ5800/PRO19607/PRO21344, Baculoviral IAP repeat-containing protein 7, Kidney inhibitor of apoptosis protein
Application Note:
Livin antibody can be used for detection of Livin by Western blot at 0.5 μg/mL. A band at 33 kDa can be detected. Antibody can also be used for immunohistochemistry starting at 5 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Background:
Livin Antibody: Apoptosis, or programmed cell death, is related to many diseases, such as cancer. Apoptosis is triggered by a variety of stimuli including members in the TNF family and prevented by the inhibitor of apoptosis (IAP) proteins. IAP proteins form a conserved gene family that binds to and inhibits cell death proteases. A novel member in the IAP protein family was recently identified and designated Livin and KIAP for kidney IAP. Livin/XIAP contains a single baculoviral IAP repeat (BIR) domain and a RING finger domain and has two isoforms termed Livin-alpha and Livin-beta. Transfection of Livin in cells resulted in protection from apoptosis induced by FADD, BAX, RIP, RIP3 and DR6. Livin has direct interaction with several caspases including caspase-3, -7, and -9. Livin inhibits the activation of caspase-9 induced by Apaf-1, cytochrome c, and dATP. The two isoforms of Livin appear to have different functions and tissue distributions.
Background References:
- Kasof GM, Gomes BC. Livin, a novel inhibitor of apoptosis protein family member. J Biol Chem. 2001;276(5):3238-46.
- Lin JH, Deng G, Huang Q, Morser J. KIAP, a novel member of the inhibitor of apoptosis protein family. Biochem Biophys Res Commun. 2000;279(3):820-31.
- Ashhab Y, Alian A, Polliack A, Panet A, Yehuda DB. Two splicing variants of a new inhibitor of apoptosis gene with different biological properties and tissue distribution pattern. FEBS Lett. 2001;495(1-2):56-60.
Buffer:
Livin Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/ml
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
Livin antibody was raised against a 17 amino acid peptide near the carboxy terminus of human Livin.
The immunogen is located within the last 50 amino acids of Livin.
The immunogen is located within the last 50 amino acids of Livin.
NCBI Gene ID #:
79444
NCBI Official Name:
baculoviral IAP repeat-containing 7
NCBI Official Symbol:
BIRC7
NCBI Organism:
Homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
33 kDa
Protein Accession #:
NP_071444
Protein GI Number:
11545910
Purification:
Livin Antibody is affinity chromatography purified via peptide column.
Research Area:
Apoptosis,Cancer
SPECIFICITY:
A lower but much weaker band at 30 kDa was detected in Raji cell lysate, which may represent the short form of Livin.
Swissprot #:
Q96CA5
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | Livin Peptide | PSI-2505P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|